Upregulation of a disintegrin and metalloprotease 8 influences tumor metastasis and prognosis in patients with osteosarcoma - PubMed (original) (raw)

Upregulation of a disintegrin and metalloprotease 8 influences tumor metastasis and prognosis in patients with osteosarcoma

Zhehai Li et al. Pathol Oncol Res. 2012 Jul.

Free article

Abstract

To investigate the clinicopathological and prognostic value of a disintegrin and metalloprotease 8 (ADAM8) in osteosarcoma. ADAM8 expression in osteosarcoma tissues was examined by immunohistochemistry in 69 patients. ADAM8 was positively expressed in 61 of 69 (88.4%) osteosarcoma specimens with cytoplasmic staining, and also increased in the specimens with recurrence (P = 0.008) and metastasis (P = 0.002). Patients with strong ADAM8 expression had significantly poorer overall survival (OS) and disease-free survival (DFS) (both P < 0.001) when compared with the patients with the weak expression of ADAM8. On multivariate analysis, ADAM8 expression was found to be an independent prognostic factor for both OS (P < 0.001) and DFS (P < 0.001). Our results suggest for the first time that ADAM8 might be applied as a novel marker for the prediction of recurrence and metastasis potency and a significant indicator of poor prognosis for patients with osteosarcoma.

PubMed Disclaimer

References

    1. J Bone Miner Res. 2001 May;16(5):814-22 - PubMed
    1. J Bone Miner Res. 2011 Jan;26(1):169-81 - PubMed
    1. Virchows Arch. 2009 Apr;454(4):441-9 - PubMed
    1. Clin Cancer Res. 2004 Dec 15;10(24):8363-70 - PubMed
    1. Acta Histochem. 2011 Jul;113(4):402-8 - PubMed

MeSH terms

Substances

LinkOut - more resources